K. Podar* and D. JagerPages 782-805 (24)
Objective: This article reviews novel immunotherapeutic approaches, which aim to restore the balance within the immunologic niche of the MM BM microenvironment.
Method: A systematic search was conducted of the Pubmed Medline, Embase, and Cochrane Library databases for primary articles, as well as of conference abstracts (e.g., of the American Society of Hematology, the American Society of Clinical Oncology, the American Association of Cancer Research, the European Hematology Association, and the Multiple Myeloma Workshop), practice guidelines, and registries of clinical trials.
Results: The inclusion of monoclonal antibodies, immune checkpoint inhibitors, chimeric antigen receptor-engineered (CAR) T cells, genetically engineered T cells, and vaccination, dendritic cellbased cancer vaccines in particular, into existing regimens is likely to significantly improve MM patient outcome in the near future.
Conclusion: Given continuing efforts to target the immune niche within the bone marrow microenvironment we are confident that the rise of immunotherapies in MM will result in long-lasting responses in many of our patients within the next decade.
Multiple Myeloma, immune microenvironment, stem cell transplantation, immunomodulatory drugs (IMiDs), antibody- and peptide- based strategies, adoptive therapy, CAR cells, TCR engineered T cells, immune checkpoint blockade, BiTE®s, vaccines.
Karl Landsteiner University of Health Sciences, University Hospital Krems, Medical Oncology, Mitterweg 10, 3500 Krems, German Cancer Research Center (DKFZ), Applied Tumor Immunity, Heidelberg